系统综述:基因6型慢性丙型肝炎病毒感染的流行病学及直接抗病毒药物应答
该系统综述检索PubMed、EMBASE和Cochrane图书馆数据库,纳入20项研究共938例基因6型丙型肝炎病毒感染患者,评估直接抗病毒药物方案的持续病毒学应答。格卡瑞韦/哌仑他韦、索磷布韦/维帕他韦(联合或不联合伏西瑞韦)及索磷布韦联合利巴韦林方案SVR12为98%-100%,来迪派韦/索磷布韦为64%-100%,索磷布韦/达拉他韦为88%-94%;失败多见于肝硬化和既往治疗经验者,严重不良事件率<5%。
要点
- 基因6型丙型肝炎病毒在东南亚丙型肝炎病毒感染者中患病率为19.9%-95.6%。
- 格卡瑞韦/哌仑他韦、索磷布韦/维帕他韦(联合或不联合伏西瑞韦)及索磷布韦联合利巴韦林方案SVR12达98%-100%。
- 肝硬化和既往治疗经验可轻度削弱直接抗病毒药物应答,失败多发生于此类人群。
核心结论
- 基因6型丙型肝炎病毒具有高度遗传多样性且在亚洲高流行,直接抗病毒药物持续病毒学应答率总体较高,肝硬化和既往治疗经验可轻度削弱应答。
- 现有证据提示直接抗病毒药物高效且安全,但仍需在基因6型高流行地区开展大规模且专门针对该基因型的研究。
研究设计与样本
- 系统综述,电子检索PubMed、EMBASE和Cochrane图书馆数据库。
- 共纳入20项研究(12项临床试验和8项观察性研究),合计938例基因6型丙型肝炎病毒感染患者。
主要发现
- 基因6型在东南亚丙型肝炎病毒感染者中患病率为19.9%-95.6%,在肝硬化患者中与较高的肝细胞癌风险相关。
- 格卡瑞韦/哌仑他韦(4项研究,108例)SVR12为98%-100%。
- 来迪派韦/索磷布韦(8项研究,427例)SVR12为64%-100%。
- 索磷布韦/维帕他韦联合或不联合伏西瑞韦(5项研究,171例)SVR12为100%。
- 索磷布韦/达拉他韦(3项研究,172例)SVR12为88%-94%;索磷布韦联合利巴韦林(3项研究,60例)SVR12为100%。
关键数值与推荐
- 治疗失败主要见于肝硬化及既往治疗经验者。
- 直接抗病毒药物耐受性良好,严重不良事件率<5%。
临床怎么用
- 当前证据提示直接抗病毒药物对基因6型丙型肝炎病毒感染高效且安全。
- 作者认为仍需在基因6型高流行地区开展大规模且专门针对该基因型的研究。
局限性
- 基因6型直接抗病毒药物应答数据相对有限。
- 治疗后失败主要见于肝硬化和既往治疗经验者。
- 作者指出需在基因6型高流行地区开展大规模且专门针对该基因型的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis C virus (HCV) genotype 6 (GT6) is predominantly encountered in Southeast Asia and data on GT6 response to direct-acting antiviral (DAA) therapy are relatively limited. AIM: To review the epidemiology and virologic outcome of DAA regimens in HCV GT6 patients. METHODS: Electronic literature search of PubMed, EMBASE, and The Cochrane Library databases were conducted. RESULTS: Hepatitis C virus genotype 6 is the most genetically diverse, has a prevalence of 19.9%-95.6% in HCV infected patients in Southeast Asia and has been associated with a higher risk of HCC in those with cirrhosis. After an extensive literature review, a total of 20 studies were selected to assess study population and treatment outcomes (total of 938 GT6 patients were included); 12 were clinical trials and eight were observational studies. Sustained virologic response at week 12 (SVR 12) following glecaprevir/pibrentasvir (n = 4; 108 patients), ledipasvir/sofosbuvir (n = 8; 427 patients), sofosbuvir/velpatasvir with or without voxilaprevir (n = 5; 171 patients), sofosbuvir/daclatasvir (n = 3; 172 patients) and sofosbuvir with ribavirin (n = 3; 60 patients) was 98%-100%, 64%-100%, 100%, 88%-94% and 100%, respectively. Failure was mostly in those with cirrhosis and prior treatment experience. DAA therapy was well tolerated and with a serious adverse event rate of <5%. CONCLUSIONS: Hepatitis C virus genotype 6 is genetically diverse and is highly prevalent in Asia. While SVR rates have been high, cirrhosis and prior treatment experience marginally compromise response to DAAs. Large scale and exclusive studies in HCV genotype 6 prevalent areas are needed, while the current evidence suggests that DAAs are highly effective and safe.
引用
- Mettikanont P, Bunchorntavakul C, Reddy KR, et al. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2019. PMID: 30687952. doi:10.1111/apt.15100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。